African Union and the Africa Centers for Disease Control and Prevention’s Africa Regulatory Taskforce has endorsed the Emergency Used Authorization for Janssen COVID-19 Vaccine
10 March 2021
These WHO interim recommendations for use of the Sinovac-CoronaVac were developed on the basis of advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) and the evidence summary included in the background document and annexes referenced below.
This document has been updat...ed: version 15 March 2022.
more
Bisher hat die STIKO empfohlen, dass alle im Ausland mit einem nicht in der EU zugelassenen Impfstoff geimpften Personen eine erneute Impfserie mit einem in der EU zugelassenen Impfstoff erhalten sollen. Ziel der im Epidemiologischen Bulletin 13/2022 veröffentlichten aktualisierten COVID-19-Impfemp...fehlung ist es, Personen, die eine COVID-19-Impfung mit einem der nicht in der EU zugelassenen Ganzvirusimpfstoffen (CoronaVac, Covilo und Covaxin) oder dem Vektor-basierten Impfstoff Sputnik V erhalten haben, mit einem Impfschutz auszustatten, der vergleichbar mit dem einer Grundimmunisierung plus Auffrischimpfung mit einem mRNA-Impfstoff ist.
more
orientaciones provisionales, primera publicación: 24 de mayo de 2021, actualización: 21 de octubre de 2021, actualización: 15 de marzo de 2022
Вакцина против COVID-19 CoronaVac производства компании Sinovac (Sinovac-CoronaVac) July 2021
This quick guide offers basic information about COVID-19, the Sinovac-CoronaVac COVID-19 vaccine and what to
expect following vaccination: ...
Временное руководство (Первый выпуск 24 мая 2021 г., Обновлено 21 октября 2021 г., Обновлено 15 марта 2022 г.
24 September 2021. The vaccine has been authorized by the Chinese National Regulatory Authority (NRA) – the National Medicinal Product Administration (NMPA) – as well as other regulatory authorities. Because WHO has granted Emergency Use Listing (EUL) for the Sinovac COVID-19 vaccine (Vero Cell ...[Inactivated]) – CoronaVac, the Africa Union and Africa CDC’s Regulatory Taskforce has endorsed the Emergency Use Authorisation for the vaccine (see scenario #1). As such, African Union Member States are recommended to waive any review processes and rely directly on the WHO EUL via the AVAREF managed pathway described in Scenario #1
more
11 august 2022, updated version
Interim guidance, 26 October 2021
This interim guidance has been developed on the basis of the advice issued by the Strategic Advisory Group of Experts (SAGE) on Immunization at its meeting on 5 October 2021.
SAGE said moderately and severely immunocompromised persons should be offered an addition...al dose of all WHO approved vaccines “since these individuals are less likely to respond adequately to vaccination following a standard primary vaccine series and are at high risk of severe COVID-19 disease.”
People aged 60 and older who received the Sinovac and Sinopharm vaccines should get a third dose too, the experts added, though use of other vaccines may also be considered depending on supply and access.
“When implementing this recommendation, countries should initially aim at maximizing 2-dose coverage in that population, and thereafter administer the third dose, starting in the oldest age groups”, they said.
SAGE has also reviewed a vaccine developed by Indian company Bharat Biotech and will issue a policy recommendation after WHO greenlights it for emergency use.
more
Existen notificaciones de eventos relacionados con la vacuna (ESAVI) de
miocarditis/pericarditis en adolescentes tras la administración de vacunas ARNm(Pfizer y Moderna) especialmente tras la segunda dosis. Al momento no seencuentra asociación entre la enfermedad y la administración de la vacuna....
more
Overview
16 Dec 2021. This interim guidance pertains to heterologous primary and heterologous boosting schedules of Covid-19 vaccines. It focuses on heterologous schedules combining multiple vaccine platforms (e.g. a vectored vaccine followed by an mRNA vaccine).
Guidelines for the Vaccination Scheme against
COVID 19: Booster Dose Health Personnel
Guidelines for the Vaccination Plan against COVID-19 in children 5 to 11 years, 11 months, 29 days with COVID-19 Vaccine Coronovac / Sinovac
PHARMA’S RESPONSE TO THE COVID-19 VACCINES CRISIS. Update Feb., 14, 2022. In September 2021, Amnesty International published A Double Dose of Inequality, which assessed the extent to which the pharmaceutical industry was restricting access to Covid-19 vaccines. This report updates that assessment ...of five leading vaccine manufacturers, AstraZeneca plc, BioNTech SE, Johnson & Johnson, Moderna Inc., and Pfizer Inc. It also includes for the first time an assessment of the two largest Chinese vaccine producers, China National Pharmaceutical Group Co., Ltd. (Sinopharm) and Sinovac Biotech Ltd. (Sinovac).
more
Wenn geflüchtete Menschen aus Kriegs- oder Krisengebieten, wie der Ukraine, nach Deutschland kommen, sollten ihnen frühzeitig alle Impfungen angeboten werden, die die Ständige Impfkommission (STIKO) für die in Deutschland lebende Bevölkerung empfiehlt. Ein aktueller Impfschutz ist entscheidend,... um die Gesundheit von Menschen, die ggf. zeitweise auf engem Raum leben müssen, individuell zu schützen und Ausbrüche zu verhindern. Die Impfempfehlungen sind für die jeweilige Altersgruppe zu berücksichtigen. Diese Handreichung beinhaltet Informationen zu relevanten Impfungen für Geflüchtete und ist für impfende Stellen sowie für die Versorgung verantwortliche Stellen gedacht.
Stand 10.3.2022
more
En Paraguay, la vacunación contra COVID-19 inició el 22 de febrero de 2021. Se han autorizado un total de siete vacunas: Bharat-Covaxin, Moderna, Pfizer-BioNTech, AstraZeneca, Sinopharm, Sputnik V- Gamaleya y CoronaVac-Sinovac. Los grupos prioritarios de vacunación están definidos según el Plan... Nacional de Vacunación contra COVID-19 en Paraguay
more